7 citations
,
February 2004 in “Clinical and Experimental Ophthalmology” Finasteride, often used for hair loss, can potentially cause cataracts.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
Moles may stop growing because of cell cooperation, not just because of aging cells.
6 citations
,
June 1983 in “Cancer” A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.
18 citations
,
February 2023 in “PLoS ONE” A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
April 2018 in “Journal of Investigative Dermatology” Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
9 citations
,
September 2017 in “PubMed” EGFR inhibitors can cause skin issues, but managing them is important for treatment success.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
1 citations
,
October 2025 in “International Journal of Molecular Sciences” Natural compounds may help treat advanced papillary thyroid cancer by targeting specific molecular pathways.
16 citations
,
April 2006 in “Pediatrics International” High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
24 citations
,
November 2008 in “Arquivos Brasileiros de Endocrinologia & Metabologia” Four patients with a type of rickets and hair loss had different mutations in their vitamin D receptor gene, causing it to not work properly.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
2 citations
,
November 2024 in “In Silico Pharmacology” 355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
4 citations
,
September 2018 in “The Journal of Dermatology” A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
December 2025 in “Clinical and Translational Science” EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
9 citations
,
June 2014 in “Nutrition and Cancer” Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
October 2006 in “Clinical Cancer Research” Antioxidants can block the cancer-fighting effects of doxorubicin.
12 citations
,
November 2006 in “Journal of thoracic oncology” A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.